Why traditional antidepressants don’t work for everyone
Traditional antidepressants often fail to bring adequate relief because they focus almost exclusively on serotonin pathways, which may not address the root neurobiological causes of depression for many individuals. This biological mismatch affects roughly one-third of people living with depression, a reality known as treatment-resistant depression .
A 2023 reanalysis of the STAR*D study revealed that the actual cumulative remission rate after up to four antidepressant trials was only 35%, far below the 67% originally reported. Even more fundamentally, recent research published in Molecular Psychiatry challenges the serotonin hypothesis itself, finding no convincing evidence that depression is caused by lower serotonin concentrations or activity.
Depression is not one uniform condition. Stanford researchers identified six distinct biological subtypes —”biotypes”—using brain imaging and machine learning. They found that different treatments work better for different subtypes, which explains why one person might respond to a particular SSRI (selective serotonin reuptake inhibitor) while another experiences no benefit.
What depression treatment without antidepressants means clinically is moving beyond daily symptom management to treatments that address root neurobiological causes, such as glutamate pathways and neural connectivity. When someone has tried multiple SSRIs or SNRIs (serotonin-norepinephrine reuptake inhibitors) without lasting improvement, the issue isn’t lack of willpower—it’s that the biological target may be mismatched. Explore the full comparison: ketamine vs SSRIs .
The evidence-based alternatives landscape
The evidence-based alternatives landscape consists of rapid-acting biological treatments, body-based therapies, and lifestyle changes—each with growing research support. These options fall into three main categories: biochemical interventions (ketamine, psilocybin), device-based treatments (TMS, neurofeedback), and body-centered approaches (EMDR, somatic work, exercise).
Ketamine-assisted therapy
IV ketamine—administered intravenously (through a vein) with 100% bioavailability for precise dosing—offers one of the fastest-acting treatments for depression available in 2026. Unlike SSRIs, which target serotonin, ketamine works on the brain’s glutamate system, promoting neuroplasticity (the brain’s ability to form new neural connections). This shift can bring symptom relief within hours rather than weeks.
A 2024 study published in the Journal of Psychopharmacology demonstrated that IV ketamine not only reduces PTSD symptoms rapidly but also sustains those improvements when paired with therapeutic integration. The research by Henry A MacConnel 1, Mitch Earleywine 2, and Steven Radowitz 3 showed rapid and sustained reduction of treatment-resistant PTSD symptoms after intravenous ketamine in a real-world, psychedelic paradigm.
Nushama’s ketamine therapy protocol includes preparation, six IV ketamine sessions over three to six weeks, continuous medical monitoring, and integration coaching to help translate the neuroplasticity window—the 24 to 72 hours after treatment when the brain is most receptive to change—into lasting behavioral shifts.
Ketamine is not a cure—it’s a catalyst. Ketamine integration is what transforms a temporary biological shift into durable healing.
Transcranial magnetic stimulation (TMS): ketamine vs TMS for depression
Ketamine and TMS represent two distinct pathways for treatment-resistant depression: ketamine works systemically through brain chemistry, while TMS uses localized magnetic pulses to stimulate specific brain regions. TMS typically targets the dorsolateral prefrontal cortex using non-invasive magnetic fields. Unlike ketamine’s rapid onset, TMS requires daily sessions over four to six weeks before full therapeutic effects are felt.
A 2025 network meta-analysis comparing IV ketamine, rTMS (repetitive transcranial magnetic stimulation), and ECT (electroconvulsive therapy) found no significant differences in response or remission rates between these treatments, though ketamine showed more favorable acceptability—meaning fewer people discontinued treatment due to side effects or discomfort.
The choice often comes down to personal preference and timeline. TMS requires five sessions per week but doesn’t produce dissociative states—temporary feelings of detachment from one’s body or surroundings—that ketamine can bring. For individuals who prefer non-medication depression treatment with a localized approach or who have contraindications to ketamine, TMS offers a well-researched alternative.
Psilocybin therapy
Psilocybin-assisted therapy for depression remains largely in clinical trial phases. COMPASS Pathways’ Phase 3 trials reported positive results in 2025, showing clinically meaningful effects in treatment-resistant depression. However, FDA review, DEA rescheduling, REMS (Risk Evaluation and Mitigation Strategy) implementation, and insurance negotiations mean broad clinical availability is still years away—potentially late 2026 or 2027 at the earliest.
For people seeking psychedelic-assisted therapy today, ketamine is the currently accessible, legally available option under medical supervision. Nushama offers both IV ketamine and FDA-approved Spravato (esketamine nasal spray). Learn more: comparing psychedelics for therapy .
Non-medication depression treatment: somatic and neural therapies
Somatic and neural therapies offer body-based and brain-based pathways as non-medication depression treatment options. These approaches are particularly valuable for individuals with trauma histories, where talk therapy alone may not fully address stored experiences in the nervous system.
-
Neurofeedback trains individuals to regulate their own brain activity in real time using visual or auditory feedback. A 2025 systematic review of fMRI-based neurofeedback found that improvements in neural regulation—particularly in the amygdala and prefrontal cortex—corresponded to observable reductions in depressive symptoms, positioning neurofeedback as a viable non-invasive treatment strategy.
- EMDR (Eye Movement Desensitization and Reprocessing) helps individuals process traumatic memories through guided eye movements or bilateral stimulation. Research suggests that EMDR ‘s body-based processing approach may help individuals who haven’t achieved remission through traditional talk therapy or medication alone, particularly those with unresolved trauma contributing to depressive symptoms.
- Somatic Experiencing works with the body’s stored responses to trauma, helping release patterns of freeze, fight, or flight. Nushama’s protocol includes somatic education in the preparation phase, teaching grounding techniques that members can use during ketamine journeys.
Lifestyle interventions: exercise, yoga, and movement
Exercise and movement-based practices are clinically significant treatments with measurable effects on brain chemistry. A 2023 systematic review examined 218 studies involving 14,170 participants and found that walking, jogging, yoga, and strength training all produced significant reductions in depressive symptoms.
These interventions work by increasing BDNF (brain-derived neurotrophic factor), regulating cortisol, improving sleep, and providing structured routine. While lifestyle changes alone may not be sufficient for severe depression, they amplify the effects of other treatments—particularly when combined with ketamine’s neuroplasticity window.
How to build a personalized treatment plan
Building a personalized treatment plan requires matching interventions to your symptom profile, treatment history, and individual neurobiology—then combining the right catalyst with ongoing professional integration support. The most durable outcomes emerge when rapid-acting treatments are paired with therapeutic work.
Assess your profile
The first step is a thorough clinical assessment that considers your depression subtype, trauma history, past medication trials, and current medical situation. Six distinct biological subtypes of depression respond to different interventions—what works for one person may not work for another.
For example, depression with significant trauma history may benefit from ketamine paired with EMDR or Somatic Experiencing. Depression with low energy may respond well to TMS or exercise combined with ketamine. Nushama’s clinical screening process includes psychiatric intake, medical review, and when indicated, laboratory work to ensure each member is a suitable candidate and to personalize the treatment protocol.
Combine modalities
The most robust treatment plans often pair a rapid-acting catalyst with ongoing therapeutic work. Many members continue their existing antidepressants, therapy, or other supports while adding ketamine or TMS under medical supervision. Thoughtful combination therapy often produces better outcomes than any single intervention alone.
A 2024 pilot study published in Psychopharmacology combining deep TMS with IV ketamine found an 80.3% response rate in the combined therapy group, though the study did not find a statistically significant advantage over TMS alone. Larger trials are needed to clarify whether combination approaches offer additive benefits. Other effective combinations include ketamine with psychotherapy, TMS with exercise protocols, or neurofeedback alongside somatic work.
Integration is the essential bridge that turns temporary biological shifts into lasting change. Ketamine integration involves translating insights and emotional shifts from treatment into concrete practices—journaling, therapy, movement, community connection—that reinforce new neural pathways during the neuroplasticity window after each session.
The role of medical supervision
Medical supervision is the safety framework that includes clinical screening, real-time monitoring during sessions, and emergency protocols to ensure alternative treatments are both effective and safe. Reputable providers offer thorough medical screening, precise dose titration, continuous monitoring, and trauma-informed care.
Nushama’s treatment includes preparation and intention setting, six IV ketamine sessions with real-time monitoring, integration coaching, and follow-up care—all under the supervision of licensed clinicians and medical staff. During each infusion, vital signs are monitored continuously, and a clinician remains present to adjust dosing or provide support as needed. See what makes Nushama different for our clinical safety framework.
Frequently asked questions
These frequently asked questions address common concerns about alternative treatments for depression—from insurance coverage and eligibility to how different options compare in practice. Understanding the logistics and practical considerations can help you make an informed decision about which treatment path is right for you.
Q: Is ketamine therapy covered by insurance?
A: Spravato (esketamine nasal spray) is often covered by insurance for qualifying diagnoses, typically requiring documentation of failed trials with at least two different antidepressants. IV ketamine is usually out-of-pocket, though superbills for potential reimbursement can be provided. Nushama offers CareCredit financing, HSA and FSA acceptance, a Hero’s Journey program reducing costs by 25% for first responders and veterans, and monthly financial-based scholarships to improve access.
Q: How do I know if I have treatment-resistant depression?
A: Treatment-resistant depression is generally defined as failing to respond adequately to two or more antidepressants from different classes at adequate doses and durations. The 2023 STAR*D reanalysis found that 65% of individuals did not achieve remission even after multiple medication trials, highlighting how common this challenge is. A thorough consultation with a clinician is necessary for formal diagnosis and to explore which treatment options align with your history and needs.
Q: Can I combine alternative treatments with my current medication?
A: Yes. Many members remain on antidepressants while undergoing ketamine or TMS under medical supervision. Your care team will review your full medication history, discuss potential interactions, and adjust as needed. Tapering, combining, or switching medications should never be done without clinical guidance. Nushama positions itself as a trusted extension of your existing mental health care, not a replacement.
Q: What is the difference between TMS and ketamine?
A: From a member experience perspective, TMS involves sitting in a chair while a magnetic coil delivers pulses to your scalp—no altered consciousness, no preparation ritual, and daily commitment over several weeks. Ketamine sessions at Nushama include a preparation phase to set intentions, a supervised infusion during which you may experience dissociation or introspective states, and integration coaching afterward to process insights. TMS is localized and methodical; ketamine is systemic and experiential.
Q: How long do ketamine results last?
A: Ketamine’s effects can provide relief for several days to a week after a single dose. Most individuals complete an initial series of six infusions over three to six weeks, with some requiring maintenance infusions every few weeks or months to sustain results. The durability of results is significantly enhanced by integration work—therapy, community support, lifestyle changes, and daily practices that reinforce new patterns during the neuroplasticity window.
If traditional antidepressants haven’t brought the relief you deserve, you’re not out of options. Today’s evidence-based landscape offers faster-acting, more personalized pathways—from IV ketamine and TMS to somatic therapies and lifestyle interventions. Nushama’s clinician-led team guides you from medical intake through preparation, treatment, and integration, ensuring safety and support at every step. Book a consultation to explore alternative pathways tailored to your needs.
